Molecular alterations for targeted therapy in metastatic gynecologic cancer
- Prosjektnummer
- 911751
- Ansvarlig person
- Helga B Salvesen
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Utenlandsstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
Cancer Epidemiol Biomarkers Prev 2013 Feb;22(2):216-23. Epub 2012 des 5
PMID: 23221126
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Gynecol Oncol 2013 Feb;128(2):327-34. Epub 2012 des 4
PMID: 23219661
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Br J Cancer 2012 Dec;107(12):1997-2004. Epub 2012 okt 25
PMID: 23099803
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Mod Pathol 2013 Mar;26(3):428-34. Epub 2012 okt 19
PMID: 23080032
A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis.
Eur J Cancer 2013 Feb;49(3):625-32. Epub 2012 okt 1
PMID: 23036850
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Clin Cancer Res 2012 Oct;18(20):5806-15. Epub 2012 aug 21
PMID: 22912389
Follow-up of gynecological cancer patients after treatment - the views of European experts in gynecologic oncology.
Acta Obstet Gynecol Scand 2012 Nov;91(11):1286-92. Epub 2012 sep 18
PMID: 22880840
Markers for individualised therapy in endometrial carcinoma.
Lancet Oncol 2012 Aug;13(8):e353-61.
PMID: 22846840
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest